Eltrombopag-based combination treatment for immune thrombocytopenia.
David Gómez-Almaguer
https://pubmed.ncbi.nlm.nih.gov/30344993/Actively Recruiting
Led by Renata PLC · Updated on 2025-02-18
100
Participants Needed
1
Research Sites
17 weeks
Total Duration
Researchers are evaluating the role of eltrombopag as a first-line therapy in patients newly diagnosed with primary immune thrombocytopenia ITP. This randomized, double-blind, placebo-controlled clinical trial will enroll 100 patients aged 18 to 70 years with platelet counts at or below 30x109L. The study aims to compare eltrombopag combined with prednisolone against prednisolone alone, assessing platelet counts and spontaneous bleeding episodes as main outcomes. Participants will be randomly assigned to one of two groups one receiving eltrombopag 25 mg daily plus prednisolone 1-2 mgkg, and the other receiving a placebo matching eltrombopag plus prednisolone, both for 28 days. Neither participants nor researchers will know who receives which treatment, ensuring a double-blind design. Patients will be followed up at 1, 2, and 4 weeks during therapy for clinical evaluation, laboratory testing, and monitoring of side effects and bleeding events. During each visit, participants will undergo history taking, physical examination, and laboratory tests including CBC, random blood sugar, liver enzymes, and creatinine. Data on bleeding events and any new symptoms will be collected through face-to-face interviews. The primary outcome is the change in platelet count and spontaneous bleeding over 28 days. Safety will be monitored by a dedicated board, and any adverse events will be managed appropriately. Statistical analysis will be conducted at study end to compare outcomes between groups.
CONDITIONS
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
M
Md Manirul Islam, MBBS,FCPS
G
Gazi Yeasinul Islam, MBBS,FCPS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Renata PLC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 28 days
Participants receive daily tablets of either Eltrombopag with Prednisolone or Prednisolone with placebo for 28 days. They are monitored for response and side effects during this period.
Visits at the end of Week 1, Week 2, and Week 4
Duration - Up to 28 days after starting therapy
Participants are evaluated by history, physical examination, and laboratory tests to assess treatment response and safety.
Visits at the end of Week 1, Week 2, and Week 4 (concurrent with treatment visits)
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David Gómez-Almaguer
https://pubmed.ncbi.nlm.nih.gov/30344993/Kristin A Shimano, Rachael F Grace, Jenny M Despotovic...
https://pubmed.ncbi.nlm.nih.gov/34452956/Drew Provan, Roberto Stasi, Adrian C Newland...
https://pubmed.ncbi.nlm.nih.gov/19846889/David Gómez-Almaguer, Perla R Colunga-Pedraza, Andrés Gómez-De León...
https://pubmed.ncbi.nlm.nih.gov/29270980/David Gómez-Almaguer, Miguel A Herrera-Rojas, José C Jaime-Pérez...
https://pubmed.ncbi.nlm.nih.gov/24802773/Renata PLC
Lead Sponsor